Summary
Soligenix Inc (Soligenix) is a late-stage biopharmaceutical company which focuses on the development of products for the treatment of serious inflammatory diseases and biodefense counter measures. It develops biotherapeutics for the treatment of orphan diseases such as cutaneous T-cell lymphoma, pediatric Crohn's disease, oral mucositis and acute radiation enteritis. It develops proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the treatment of gastrointestinal disorders that are characterized by high inflammation, including pediatric Crohn’s disease, acute radiation enteritis and oral mucositis. The company has active development programs for RiVax, a ricin toxin vaccine; VeloThrax, an anthrax vaccine; and OrbeShield, a gastrointestinal acute radiation syndrome therapeutic. These vaccine programs are supported by ThermoVax, a heat stabilization technology. Soligenix is headquartered in Princeton, New Jersey, the US.
Soligenix Inc (SNGX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Soligenix Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Soligenix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Soligenix Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Soligenix Acquires SGX301 from Hy Biopharma for USD14 Million 12
Soligenix Acquires SGX94, Innate Defense Regulator Clinical Program 14
Partnerships 15
Soligenix Enters into Co-Development Agreement with University of Hawaii at Manoa and Hawaii Biotech 15
Soligenix Expands its Development Agreement with Emergent BioSolutions 16
Soligenix Enters into Contract with National Institute of Allergy and Infectious Diseases and Biomedical Advanced Research and Development Authority 17
Soligenix Enters Into Co-Marketing Agreement With SciClone Pharma For SGX942 18
Soligenix Enters Into Co-Development Agreement With Intrexon 19
Soligenix Enters Into Agreement With Infectious Disease Research Institute To Develop Biodefense Vaccines 20
Licensing Agreements 22
SciClone Pharma Enters into Licensing Agreement with Soligenix 22
Soligenix Enters into Licensing Agreement with New York University and Yeda Research and Development 23
Soligenix Enters Into Licensing Agreement With Intrexon To Develop Melioidosis Therapy 24
Soligenix Enters Into Option For License Agreement With Harvard University 26
Soligenix Expands Licensing Agreement With Sigma-Tau Pharma For orBec 27
Soligenix Enters Into Licensing Agreement With University Of Colorado 29
Equity Offering 30
Soligenix Plans to Raise up to USD4.8 Million in Public Offering of Shares 30
Soligenix Raises USD5.3 Million in Public Offering of Shares and Warrants 31
Soligenix to Raise USD12 Million in Private Placement of Shares 33
Soligenix Raises USD2.3 Million in Public Offering of Shares 34
Soligenix Completes First Tranche Of Private Placement Of Shares For US$0.6 Million 36
Soligenix Completes Private Placement Of Units For US$7 Million 37
Soligenix Inc - Key Competitors 38
Soligenix Inc - Key Employees 39
Soligenix Inc - Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Recent Developments 41
Strategy And Business Planning 41
Jan 26, 2016: Soligenix Provides 2016 Business Outlook 41
Financial Announcements 43
Aug 11, 2017: Soligenix Announces Recent Accomplishments And Second Quarter 2017 Financial Results 43
May 11, 2017: Soligenix Announces Recent Accomplishments And First Quarter 2017 Financial Results 45
Mar 27, 2017: Soligenix Announces Recent Accomplishments And Year-End 2016 Financial Results 47
Nov 10, 2016: Soligenix Announces Recent Accomplishments and Third Quarter 2016 Financial Results Highlighted by Revenues of $3.0 Million 49
Aug 11, 2016: Soligenix Announces Recent Accomplishments and Second Quarter 2016 Financial Results Highlighted by Revenues of $3.2 Million 51
May 12, 2016: Soligenix Announces Recent Accomplishments and First Quarter 2016 Financial Results 52
Mar 24, 2016: Soligenix Announces Recent Accomplishments and Year-End 2015 Financial Results 53
Corporate Communications 55
Jun 20, 2016: Soligenix Appoints Karen Krumeich, as Chief Financial Officer 55
Government and Public Interest 56
Oct 17, 2016: Soligenix to Receive $530,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program 56
Product News 57
05/25/2016: Soligenix Receives Additional National Institute of Allergy and Infectious Diseases Funding to Advance Development of Heat Stable Ricin Vaccine 57
05/05/2016: Soligenix Receives Additional NIAID Funding to Advance Development of Ricin Vaccine 59
03/17/2016: Soligenix Receives Additional NIAID Funding to Advance Development of Heat Stable Ricin Vaccine RiVax 60
Product Approvals 62
Feb 02, 2017: Soligenix Announces SGX301 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency 62
Jan 05, 2017: Soligenix Receives Positive Scientific Advice from the European Medicines Agency for SGX942 in the Treatment of Oral Mucositis in Head and Neck Cancer Patients 63
Dec 12, 2016: Soligenix Announces SGX942 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency 64
Oct 25, 2016: Soligenix Receives European Medicines Agency Designation as Small and Medium Enterprise 65
Aug 18, 2016: FDA Grants Soligenix Orphan Drug Designation for Dusquetide for Treatment of Macrophage Activation Syndrome 66
May 31, 2016: FDA Grants Soligenix “Fast Track” Designation for SGX943 for the Treatment of Melioidosis 67
Clinical Trials 68
Dec 08, 2016: Origins of Innate Defense Regulators and Review of the SGX942 Phase 2 Study Results in Oral Mucositis 68
Dec 08, 2016: Soligenix Announces Positive Long-Term Follow-up Results from its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 70
Oct 18, 2016: Soligenix Announces Publication of its Phase 2 Clinical Trial Results of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 72
Oct 13, 2016: Soligenix Announces Poster Presentations from its Gastrointestinal Acute Radiation Syndrome Program at the 2016 Radiation Research Society Meeting 74
Oct 11, 2016: Soligenix Announces Poster Presentation of its Dusquetide Orphan Program at the 2016 NORD Rare Diseases and Orphan Products Breakthrough Summit 75
Oct 11, 2016: Soligenix Announces Poster Presentation of its Ricin Vaccine Orphan Program at the 2016 NORD Rare Diseases and Orphan Products Breakthrough Summit 76
Jul 25, 2016: Soligenix Receives Additional BARDA and NIAID Funding to Advance Development of OrbeShield in GI ARS 78
Jul 18, 2016: Soligenix Announces Presentation of Positive Preliminary Results of a Heat Stable Ebola Vaccine Formulation 79
Jun 06, 2016: Soligenix Announces Presentation of Phase 2 Oral Mucositis Clinical Trial Results at the 2016 Multinational Association for Supportive Care in Cancer Conference 81
Mar 29, 2016: Soligenix Announces Publication of Preclinical Efficacy Results with Dusquetide in Infectious Disease 83
Appendix 85
Methodology 85
About GlobalData 85
Contact Us 85
Disclaimer 85
List of Tables
Soligenix Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Soligenix Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Soligenix Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Soligenix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Soligenix Acquires SGX301 from Hy Biopharma for USD14 Million 12
Soligenix Acquires SGX94, Innate Defense Regulator Clinical Program 14
Soligenix Enters into Co-Development Agreement with University of Hawaii at Manoa and Hawaii Biotech 15
Soligenix Expands its Development Agreement with Emergent BioSolutions 16
Soligenix Enters into Contract with National Institute of Allergy and Infectious Diseases and Biomedical Advanced Research and Development Authority 17
Soligenix Enters Into Co-Marketing Agreement With SciClone Pharma For SGX942 18
Soligenix Enters Into Co-Development Agreement With Intrexon 19
Soligenix Enters Into Agreement With Infectious Disease Research Institute To Develop Biodefense Vaccines 20
SciClone Pharma Enters into Licensing Agreement with Soligenix 22
Soligenix Enters into Licensing Agreement with New York University and Yeda Research and Development 23
Soligenix Enters Into Licensing Agreement With Intrexon To Develop Melioidosis Therapy 24
Soligenix Enters Into Option For License Agreement With Harvard University 26
Soligenix Expands Licensing Agreement With Sigma-Tau Pharma For orBec 27
Soligenix Enters Into Licensing Agreement With University Of Colorado 29
Soligenix Plans to Raise up to USD4.8 Million in Public Offering of Shares 30
Soligenix Raises USD5.3 Million in Public Offering of Shares and Warrants 31
Soligenix to Raise USD12 Million in Private Placement of Shares 33
Soligenix Raises USD2.3 Million in Public Offering of Shares 34
Soligenix Completes First Tranche Of Private Placement Of Shares For US$0.6 Million 36
Soligenix Completes Private Placement Of Units For US$7 Million 37
Soligenix Inc, Key Competitors 38
Soligenix Inc, Key Employees 39
Soligenix Inc, Subsidiaries 40
List of Figures
Soligenix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Soligenix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
